secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-116154
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon FY2025 net loss $45.6M; tegoprubart data shows insulin independence in T1D islet transplant
--------------------------------------------------------------------------------

- Net loss for FY2025 was $45.6M ($0.52/share) vs $36.2M loss in FY2024; non-GAAP net loss (excl warrant gain) was $79.1M.
- R&D expenses rose to $66.3M from $52.0M, driven by clinical trial expansion and manufacturing scale-up.
- Phase 1b kidney transplant data: eGFR improved from 67.0 at 12mo to 74.2 at 24mo; no rejection or graft loss in 8 patients.
- In T1D islet transplant study, all 10 patients >4 weeks post-transplant achieved 100% insulin independence with mean HbA1c ~5.35%.
- Tegoprubart received FDA Orphan Drug designation for liver transplantation; Phase 3 kidney trial initiation pending FDA guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000119312526116154/0001193125-26-116154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000119312526116154/eldn-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-116154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer